Design Therapeutics, Inc. (DSGN): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of DSGN were reported in the last 12 months. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Design Therapeutics
From the latest filingsOverall: more selling than buying. Famous investors mostly sold. Funds mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns DSGN
136 funds and institutions reported DSGN shares worth $630M at the end of Q2 2026, about 70% of the company. The largest holder is SR One Capital Management, LP with 10.4%.
Funds and institutions (13F) 70%Everyone else 30%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| SR One Capital Management, LP | 6.53M | 10.45% | $94.4M | No change |
| Logos Global Management LP | 3.00M | 4.80% | $43.4M | +54% |
| Baker Bros. Advisors LP | 2.68M | 4.29% | $38.8M | +4% |
| Driehaus Capital Management LLC | 2.66M | 4.26% | $38.5M | +53% |
| BlackRock, Inc. | 2.66M | 4.26% | $38.5M | +25% |
| Point72 Asset Management, L.P. | 2.37M | 3.79% | $34.2M | -13% |
| Trails Edge Capital Partners, LP | 2.00M | 3.20% | $29M | +135% |
| Frazier Life Sciences Management, L.P. | 1.81M | 2.90% | $26.2M | – |
| Vivo Capital, LLC | 1.61M | 2.58% | $23.3M | No change |
| Vanguard Capital Management LLC | 1.57M | 2.52% | $22.7M | +16% |
| Caption Management, LLC | 1.12M | 1.79% | $16.2M | +1189% |
| Almitas Capital LLC | 1.03M | 1.64% | $14.9M | -33% |
| Geode Capital Management, LLC | 958,417 | 1.53% | $13.9M | +38% |
| Sofinnova Investments, Inc. | 865,135 | 1.39% | $12.5M | – |
| FMR LLC (Fidelity) | 776,462 | 1.24% | $11.2M | -3% |
| Morgan Stanley | 765,425 | 1.23% | $11.1M | +17% |
| State Street Corp | 736,221 | 1.18% | $10.7M | +12% |
| Woodline Partners LP | 700,354 | 1.12% | $10.1M | -27% |
| Dimensional Fund Advisors LP | 694,743 | 1.11% | $10.1M | +61% |
| Goldman Sachs Group Inc | 656,584 | 1.05% | $9.5M | +30% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
No DSGN insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
DSGN short interest
Moderate short interest. 9.9% of DSGN shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went up 117%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 6.31M DSGN shares were sold short, 9.9% of the shares outstanding, down 5.1% from the report before. At the average daily volume of 389,184 shares, buying them all back would take about 16.2 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 6.31M | 9.86% | -5% | 389,184 | 16.2 |
| Oct 15, 2026 | 6.65M | 10.63% | +1% | 554,993 | 12.0 |
| Sep 30, 2026 | 6.62M | 10.57% | +21% | 761,007 | 8.7 |
| Sep 15, 2026 | 5.46M | 8.73% | -1% | 751,944 | 7.3 |
| Aug 31, 2026 | 5.54M | 8.86% | -6% | 617,267 | 9.0 |
| Aug 14, 2026 | 5.93M | 9.47% | -0% | 389,063 | 15.2 |
| Jul 31, 2026 | 5.95M | 9.51% | +5% | 497,787 | 12.0 |
| Jul 15, 2026 | 5.67M | 9.08% | -1% | 891,591 | 6.4 |
| Jun 30, 2026 | 5.72M | 9.15% | +23% | 1.11M | 5.2 |
| Jun 15, 2026 | 4.63M | 7.42% | +19% | 741,594 | 6.2 |
| May 29, 2026 | 3.88M | 6.21% | +34% | 2.03M | 1.9 |
| May 15, 2026 | 2.90M | 4.65% | +25% | 543,946 | 5.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Design Therapeutics company events
Design Therapeutics filed 8 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 4, 2026.
- Nov 4, 2026ResultsReleased financial results. Filing
- Aug 3, 2026ResultsReleased financial results. Filing
- Jun 11, 2026VoteReported shareholder vote results. Filing
- May 18, 2026AnnouncementDesign Therapeutics, Inc. announced biomarker and clinical data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich ataxia. Filing
- Apr 28, 2026ResultsReleased financial results. Filing
- Apr 1, 2026LeadershipThe Board appointed David Shapiro, M.D., to the Board as a Class III director, effective immediately, with a term ending at the Company’s 2027 annual meeting of stockholders. Filing
- Mar 9, 2026ResultsReleased financial results. Filing
- Jan 30, 2026LeadershipDeepa Prasad notified Design Therapeutics, Inc. of her decision to resign from the Company’s Board of Directors, effective February 1, 2026, due to required conflict-avoidance policies associated with her newly appointed role with a major bank. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Design Therapeutics financials
Famous investors that hold DSGN
3 of the 50 well-known investors we track reported holding DSGN in their latest 13F filing. The largest position is Steve Cohen's, worth $29.1M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Steve Cohen · Point72 Asset Management | Q3 2026 | 2.32M | $29.1M | 0.0% | -2% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 301,800 | $3.8M | 0.0% | -22% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 76,300 | $959K | 0.0% | -7% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named DSGN in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | DRIEHAUS CAPITAL MANAGEMENT LLC | 13G | 5.8% |
| Nov 16, 2026 | DRIEHAUS CAPITAL MANAGEMENT LLC | 13G | 5.8% |
Questions about Design Therapeutics, Inc. (DSGN) stock
Who owns the most DSGN stock?
The largest reported owner of Design Therapeutics, Inc. (DSGN) is SR One Capital Management, LP, with 10.4% of the company. In total, 136 funds and institutions reported holding DSGN at the end of Q2 2026, together about 70% of the shares. See the largest owners.
Are DSGN insiders buying or selling?
No DSGN insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in DSGN?
As of Oct 30, 2026, 6.31M DSGN shares were sold short, 9.9% of the shares outstanding, down 5.1% from the report before. At the average daily volume of 389,184 shares, buying them all back would take about 16.2 trading days (days to cover). See the history.
Which famous investors hold DSGN?
3 of the 50 well-known investors we track reported DSGN in their latest 13F filing, including Steve Cohen, Jim Simons, Ken Griffin. The largest position is worth $29.1M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.